Oxiglutatione
Bss, Navstel (oxiglutatione) is a small molecule pharmaceutical. Oxiglutatione was first approved as Bss plus on 1982-01-01. The pharmaceutical is active against glutathione reductase, mitochondrial.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Bss (discontinued: Methotrexate, Navstel)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Calcium chloride
+
Dextrose
+
Magnesium chloride
+
Oxiglutatione
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
+
Sodium phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NAVSTEL | Alcon Research | N-022193 DISCN | 2008-07-24 | 1 products |
Hide discontinued
Calcium chloride
+
Dextrose
+
Glutathione disulfide
+
Magnesium chloride
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
+
Sodium phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BSS PLUS | Alcon Research | N-018469 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | 1 | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Liver failure | D017093 | — | K72.9 | — | 1 | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
| Reperfusion injury | D015427 | — | — | — | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | — | 1 |
| Preleukemia | D011289 | — | — | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oxiglutatione |
| INN | oxiglutatione |
| Description | Glutathione disulfide (GSSG) is a disulfide derived from two glutathione molecules.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 27025-41-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1372 |
| ChEBI ID | 17858 |
| PubChem CID | 11215652 |
| DrugBank | DB03310 |
| UNII ID | ULW86O013H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GSTM2
GSTM2
Organism
Homo sapiens
Gene name
GSTM2
Gene synonyms
GST4
NCBI Gene ID
Protein name
glutathione S-transferase Mu 2
Protein synonyms
epididymis secretory sperm binding protein, glutathione S-alkyltransferase M2, glutathione S-aralkyltransferase M2, glutathione S-aryltransferase M2, glutathione S-transferase 4, glutathione S-transferase M1, glutathione S-transferase M2 (muscle), glutathione S-transferase mu 2 (muscle), GST class-mu 2, GST, muscle, GSTM2-2, S-(hydroxyalkyl)glutathione lyase M2
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Methotrexate – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,176 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
260 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use